Predicting heart failure using the plasma proteome
ABSTRACT
To determine whether the plasma proteome adds value to established predictors in heart failure (HF) with reduced ejection fraction (HFrEF). We sought to derive and validate a plasma proteomic risk score (PRS) for survival in patients with HFrEF (HFrEF-PRS).
Until recently, proteomics had not been as thoroughly explored partly due to comparatively low-throughput. However, emerging proteomic technologies have recently matured and newer high-throughput techniques now allow larger scale proteomic characterization. One of these newer technological innovations, enhanced aptamer-based assays, has enabled a massively expanded candidate approach that borders on true proteomics in scale; thousands of protein-derived factors can be efficiently assayed simultaneously in a small biologic sample. In this webinar, you will explore this new large-scale protein array using an established HF patient registry to understand how the plasma proteome could meaningfully predict the risk of death or HF worsening and add to best conventional risk stratification, including clinical score and natriuretic peptides. By using the circulating proteome to improve risk prediction, it could add a new tool to help manage patients with HF and contribute to discovery of novel HF markers and pathways.
David E. Lanfear, MD, MS, FAHA, FACC, FHFSA
Section Head, Advanced Heart Failure and Transplant Cardiology Co-Director, Center for Individualized and Genomic Medicine Research Professor of Medicine, WSU-SoM Henry Ford Hospital
DAVID E. LANFEAR, MD, MS, Research Professor of Medicine, is Head of the Advanced Heart Failure and Transplant Cardiology at Henry Ford Hospital in Detroit, and Co-Director of the Center for Individualized and Genomic Medicine Research (CIGMA). Dr. Lanfear is a practicing transplant cardiologist, a clinician scientist with a track record of NIH-funded projects on precision medicine and genomics as well as an active trialist with experience in single and multicenter clinical trials. He has more than 140 published manuscripts, reaching high-impact journals including JAMA and NEJM. He is Associate Editor at Circulation: Heart Failure and is on the Editorial Boards of JCF, Heart Failure Reviews, JACC:Cardio-oncology, JACC: Basic to Translational Science.
More webinars
WebinarDetecting growing tumors through changes in the plasma proteome
In this GEN webinar, Nebojsa Janjic, PhD, will discuss the need for a reliable blood-based screening method capable of detecting cancers earlier. During the webinar, he will highlight results from a study involving researchers from SomaLogic and the University of Colorado School of Medicine that used a test capable of measuring 5000 proteins simultaneously.
WebinarIdentifying Biomarkers for IBD Diagnosis and Management
In this webinar, you’ll hear how proteomics technology can enhance the identification of biomarkers for the accurate diagnosis of Crohn’s disease and ulcerative colitis, as well as the identification of biomarkers that predict response to TNF inhibitors and other biologics in patients with IBD.
WebinarBoutique Webinar : Predicting Pregnancy Complications with High-Plex Proteomics
The interdisciplinary team, comprising 10-15 scientists and clinician-scientists, is dedicated to advancing diagnostics and therapeutics aimed at enhancing maternal and fetal care. Their primary focus lies in the development of interventions for conditions such as ectopic pregnancy and preeclampsia, alongside the creation of diagnostics to prevent stillbirth.